Vedolizumab is safe and effective in the treatment of X-linked agammaglobulinemia-associated inflammatory bowel disease

J Allergy Clin Immunol Pract. 2021 Feb;9(2):1006-1007. doi: 10.1016/j.jaip.2020.11.040. Epub 2020 Nov 28.

¹ Department of Immunology, Perth Children's Hospital, Perth, WA, Australia; Department of Immunopathology, PathWest, Perth, WA, Australia.
² Department of Gastroenterology, Perth Children's Hospital, Perth, WA, Australia.
³ Department of Gastroenterology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
⁴ Department of Immunology, Perth Children's Hospital, Perth, WA, Australia; Department of Immunopathology, PathWest, Perth, WA, Australia. Electronic address: [email protected].

No abstract available

Publication types